GFRD Galliford Try Holdings plc
Galliford Try Holdings plc, together with its subsidiaries, operates in the construction business in the United Kingdom. The company operates through Building and Infrastructure, and Investments segments. It engages in t…
Industry Peers
Engineering & Construction| Headline | Source | Time |
|---|---|---|
Yesterday | ||
Older | ||
![]() Galliford Try (LSE:GFRD) Stock Gets Fair Value Boost On Lower Risk And Margin Views The latest analyst work on Galliford Try Holdings reflects a shift in fair value, with the model price target moving from £6.52 to £7.54 per share. Analysts link this change to updated views on risk around future cash flows and how much scope they see for the company to deliver on its plans. As you read on, you will see how this evolving narrative may shape the way you track Galliford Try Holdings from here. Analyst Price Targets don't always capture the full story. Head over to our Company... | ||
![]() Pan African Resources, Galliford Try, IP Group, hVIVO, accesso Technology Group, Helix Exploration Pan African Resources PLC (LSE:PAF, OTCQX:PAFRY, JSE:PAN) has reported record production and earnings for FY2026 after a 40% jump in output. It's now moved from net debt to a "really healthy cash balance." CEO Cobus Loots says its 2027 production target is not a massive stretch. Galliford Try Holdings PLC (LSE:GFRD, FRA:3WC) has delivered a sixth straight year of growth, with profit up 24%. CFO Kris Hampson says the group is well positioned, with a very healthy order book. IP Group PLC (LSE:IPO) has made a strong start to 2026, with NAV per share reaching around 117p. Cash proceeds have already topped £85 million year to date. CEO Greg Smith says more realisation opportunities lie ahead. hVIVO PLC (AIM:HVO) has posted a record order book of £72 million after its first pivotal Phase 3 trial with ILiAD. It's now targeting £47 million in full-year revenue, and CEO Mo Khan says the order book provides good visibility. Accesso Technology Group PLC (LSE:ACSO, OTC:LOQPF, FRA:LQG) has seen cash EBITDA jump almost 50% after tightening up its cost base. It's now betting big on its "AI first" accesso Intelligence platform. CEO Lee Cowie says accessoPay represents another opportunity. HeLIX Exploration PLC (AIM:HEX, OTCQB:HHEXF) has spudded the Ollie #1 well, testing the northern extension of its Rudyard helium field in Montana. CEO Bo Sears highlighted the presence of multiple stacked pays at Rudyard, with the company examining every formation encountered. Follow us and subscribe on YouTube, our social channels, and on proactiveinvestors.co.uk. | ||
VVox Markets | ||
![]() Galliford Try H2 Earnings Call Highlights Galliford Try (LON:GFRD) reported a sixth consecutive year of improvement in its key financial measures for the year ended 2026, supported by margin gains in its Building and Infrastructure divisions, strong cash generation and a growing order book. The construction group said revenue increased 3% | ||
![]() Galliford Try's Kris Hampson: Sixth straight year of growth as order book hits £4.3bn Galliford Try Holdings PLC (LSE:GFRD, FRA:3WC) chief financial officer Kris Hampson spoke with Proactive's Stephen Gunnion about the construction group's latest results, growing order book, margin progression and outlook for 2027, as well as its approach to acquisitions and shareholder returns. Hampson said Galliford Try delivered a sixth consecutive year of growth across key metrics, supported by its building, infrastructure and specialist services operations. Adjusted profit before tax rose 24% on revenue growth of 3% to nearly £56 million, with adjusted divisional operating margin advancing from 3% to 3.5% and average cash up 21% to £216.2 million. "We make revenue, we turn it into profit, and we turn that profit into cash," Hampson said. Looking ahead, he highlighted the £4.3 billion order book, up 5%, with more than 90% of current-year revenue already secured, alongside 60% for 2028. He said 91% of the order book sits within long-term frameworks and 95% is with government and regulated clients. Hampson also discussed opportunities across water, highways, education and affordable housing, including growth tied to AMP8, newer frameworks on improved terms, and expects continued progression towards the group's 4% adjusted operating margin target for 2030. On capital allocation, Galliford Try announced a £15 million share buyback alongside its results, following last year's £10 million buyback. Hampson also discussed the company's active M&A pipeline and its commitment to maintaining a dividend at 1.8 times cover based on adjusted EPS. Visit Proactive’s YouTube channel for more interviews and market updates. Give the video a like, subscribe to the channel and enable notifications so you don’t miss future content. Read Proactive's Editorial Policy here: https://www.proactiveinvestors.co.uk/pages/editorialPolicy #GallifordTry #GFRD #KrisHampson #UKConstruction #Infrastructure #UKInfrastructure #Construction #Investing #InvestorNews #FinancialResults #OrderBook #ShareBuyback #Dividend #MergersAndAcquisitions #AMP8 #WaterInfrastructure #AffordableHousing #ProactiveInvestors #Proactive | ||
![]() Diversified Energy, Galliford Try, Sunda Energy, Rockfire Resources, Solvonis Therapeutics, Futura Diversified Energy Company PLC (LSE:DEC, NYSE:DEC, FRA:DG20) has agreed its biggest-ever deal, paying $1.8 billion for Permian Basin producer Birch. It should boost production by around 35%. Galliford Try Holdings PLC (LSE:GFRD, FRA:3WC) has landed a £110 million contract to improve water quality in the River Mease. It'll build a 23-kilometre pipeline for Severn Trent. Sunda Energy PLC (AIM:SNDA, FRA:GHA0) has seen a big upgrade at its Halcon prospect offshore the Philippines, now assigned 8 trillion cubic feet of gas resources. That gives Sunda a 3 Tcf net share. Rockfire Resources PLC (LSE:ROCK) says early processing tests at its Molaoi zinc project in Greece look promising. The ore's classed as "Medium-Hard," sitting comfortably within normal grinding energy requirements. Solvonis Therapeutics PLC (LSE:SVNS, OTC:SLVNF) has been granted a key European patent allowance for its PTSD drug candidate SVN-114. The company calls it a "vital milestone" strengthening its IP position. Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX) has kicked off a formal sale process for the business behind its Eroxon gel. It's also raised £1.6 million to fund the process through to a decision. Follow us and subscribe on YouTube, our social channels, and on proactiveinvestors.co.uk. | ||




